JP2008535850A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535850A5 JP2008535850A5 JP2008505580A JP2008505580A JP2008535850A5 JP 2008535850 A5 JP2008535850 A5 JP 2008535850A5 JP 2008505580 A JP2008505580 A JP 2008505580A JP 2008505580 A JP2008505580 A JP 2008505580A JP 2008535850 A5 JP2008535850 A5 JP 2008535850A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- flumazenil
- administered
- pharmaceutical composition
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims description 14
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 13
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 13
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical group C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 claims 16
- 229960004381 flumazenil Drugs 0.000 claims 16
- 238000004519 manufacturing process Methods 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims 6
- 229960004039 finasteride Drugs 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 5
- 244000025254 Cannabis sativa Species 0.000 claims 5
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims 5
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims 5
- 206010012335 Dependence Diseases 0.000 claims 5
- 230000001430 anti-depressive effect Effects 0.000 claims 5
- 239000000935 antidepressant agent Substances 0.000 claims 5
- 229940005513 antidepressants Drugs 0.000 claims 5
- 229960002715 nicotine Drugs 0.000 claims 5
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 5
- 229940127240 opiate Drugs 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims 4
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims 4
- 229940075993 receptor modulator Drugs 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229940123934 Reductase inhibitor Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 210000004556 brain Anatomy 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66903305P | 2005-04-07 | 2005-04-07 | |
| US72897905P | 2005-10-21 | 2005-10-21 | |
| US72901305P | 2005-10-21 | 2005-10-21 | |
| PCT/US2006/013099 WO2006110557A2 (en) | 2005-04-07 | 2006-04-07 | Methods for the treatment of substance abuse and dependence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535850A JP2008535850A (ja) | 2008-09-04 |
| JP2008535850A5 true JP2008535850A5 (enExample) | 2009-01-15 |
Family
ID=37087555
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505625A Withdrawn JP2008538748A (ja) | 2005-04-07 | 2006-04-06 | 不安、物質乱用及び依存の予防のための改良型方法及び組成物 |
| JP2008505599A Pending JP2008535852A (ja) | 2005-04-07 | 2006-04-07 | 不安関連障害の治療方法 |
| JP2008505580A Pending JP2008535850A (ja) | 2005-04-07 | 2006-04-07 | 物質乱用及び依存の治療方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505625A Withdrawn JP2008538748A (ja) | 2005-04-07 | 2006-04-06 | 不安、物質乱用及び依存の予防のための改良型方法及び組成物 |
| JP2008505599A Pending JP2008535852A (ja) | 2005-04-07 | 2006-04-07 | 不安関連障害の治療方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20080207601A1 (enExample) |
| EP (3) | EP1868593A2 (enExample) |
| JP (3) | JP2008538748A (enExample) |
| KR (2) | KR20080004581A (enExample) |
| AU (3) | AU2006235318A1 (enExample) |
| BR (2) | BRPI0609744A2 (enExample) |
| CA (3) | CA2604887A1 (enExample) |
| CR (2) | CR9410A (enExample) |
| IL (2) | IL186450A0 (enExample) |
| MX (2) | MX2007012355A (enExample) |
| NO (2) | NO20075155L (enExample) |
| WO (3) | WO2006110642A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050192271A1 (en) | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| AU2006235318A1 (en) * | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
| US20090269795A1 (en) * | 2007-03-09 | 2009-10-29 | The Research Foundation Of State University Of New York | Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability |
| US8586634B2 (en) * | 2007-06-15 | 2013-11-19 | University Of Florida Research Foundation, Inc. | Therapeutic compounds |
| CA2707980C (en) | 2007-12-17 | 2015-05-12 | Labopharm Inc. | Misuse preventative, controlled release formulation |
| ITRM20080436A1 (it) * | 2008-08-06 | 2010-02-07 | Francesco Marrosu | Uso della finasteride e di altre sostanze inibenti l'enzima 5-a-reduttasi per la prevenzione e la cura dei disturbi dell'impulso e dell'aggressivita' |
| TWI630208B (zh) | 2008-12-08 | 2018-07-21 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
| CA2746888C (en) | 2008-12-16 | 2015-05-12 | Labopharm (Barbados) Limited | Misuse preventative, controlled release formulation |
| WO2010094074A1 (en) * | 2009-02-20 | 2010-08-26 | Palmaya Pty Ltd | Pharmaceutical preparation and delivery system |
| WO2011073985A1 (en) * | 2009-12-14 | 2011-06-23 | Coeruleus Ltd. | Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs |
| CA2785056A1 (en) | 2009-12-22 | 2011-07-21 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
| WO2012006683A1 (en) * | 2010-07-16 | 2012-01-19 | Controlled Release Technologies Pty Ltd | Pharmaceutical compositions for sustained delivery of benzodiazepine antagonists |
| US8968722B2 (en) * | 2010-12-29 | 2015-03-03 | Mead Johnson Nutrition Company | Milk-based nutritional compositions containing lactoferrin and uses thereof |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| CA2862076C (en) | 2012-01-23 | 2020-04-21 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating cns disorders |
| PL2887944T3 (pl) * | 2012-08-21 | 2022-02-21 | Sage Therapeutics, Inc. | Allopregnanolon do leczenia lekoopornego stanu padaczkowego |
| JP2016501876A (ja) | 2012-11-30 | 2016-01-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ステロイドの抗痙攣活性 |
| SG10201706063UA (en) * | 2012-12-18 | 2017-09-28 | Univ Washington | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same |
| GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
| EP3160969B1 (en) * | 2014-06-26 | 2023-09-13 | The Johns Hopkins University | Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN113616661A (zh) | 2016-03-08 | 2021-11-09 | 萨奇治疗股份有限公司 | 神经活性类固醇、其组合物及用途 |
| US20180050005A1 (en) * | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Concentrated Solution of 17-Hydroxydocosahexaenoic Acid |
| WO2018127601A1 (en) * | 2017-01-09 | 2018-07-12 | Asarina Pharma Ab | Injectable suspensions |
| CN111050801B (zh) * | 2017-03-28 | 2023-03-28 | Ldn制药有限公司 | 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂 |
| GB201704909D0 (en) | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | Cancer therapy |
| KR101898814B1 (ko) | 2017-09-07 | 2018-09-13 | 백창목 | 도어 개폐용 도어록 |
| WO2019055939A1 (en) * | 2017-09-18 | 2019-03-21 | SEN-JAM Pharmaceutical LLC | METHODS AND COMPOSITIONS FOR INHIBITING SYMPTOMS ASSOCIATED WITH OPIOID WEANING |
| US11129803B2 (en) | 2017-09-18 | 2021-09-28 | SEN-JAM Pharmaceutical LLC | Methods and compositions to inhibit tolerance to opioids |
| US12414956B2 (en) | 2017-09-20 | 2025-09-16 | Calista Capital, Llc | Method for smoking cessation |
| WO2019060171A1 (en) * | 2017-09-20 | 2019-03-28 | Calista Capital, Llc | METHOD FOR STOPPING TOBACCO |
| EP3482751A1 (en) * | 2017-11-14 | 2019-05-15 | LDN Pharma Limited | Cancer treatment |
| KR20200140832A (ko) * | 2018-04-05 | 2020-12-16 | 아사리나 파마 에이피에스 | 물질 금단 장애를 치료하기 위한 gaba-a 길항제 |
| CA3095682A1 (en) * | 2018-04-06 | 2019-10-10 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of substance use disorders |
| WO2020061410A1 (en) | 2018-09-20 | 2020-03-26 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering |
| WO2020181340A1 (en) * | 2019-03-14 | 2020-09-17 | Palmaya Pty Ltd | Treatment of inflammatory diseases of the central nervous system |
| HUE064596T2 (hu) | 2019-08-26 | 2024-03-28 | Period Pill Bv | Menstruációs ciklus által kiváltott tünetek kezelése |
| US12233070B2 (en) | 2020-06-30 | 2025-02-25 | University Of Mississippi Medical Center | Methods for treating benzodiazepine misuse/use disorder |
| CA3201498A1 (en) * | 2020-11-27 | 2022-06-02 | Trexapharm Pty Ltd | Compositions comprising flumazenil and naltrexone and methods for use thereof |
| US20220265601A1 (en) * | 2021-02-10 | 2022-08-25 | David Alan Heldreth, JR. | Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses. |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4034087A (en) * | 1973-12-17 | 1977-07-05 | The Regents Of The University Of Michigan | Pharmaceutical composition and process of treatment |
| US4595684A (en) * | 1985-08-16 | 1986-06-17 | Ciba-Geigy Corporation | Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof |
| US5175155A (en) * | 1991-10-07 | 1992-12-29 | Sterling Winthrop Inc. | Win 49596-finasteride method of use and compositions |
| DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| FR2719843B1 (fr) * | 1994-05-10 | 1996-06-07 | Synthelabo | Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique. |
| US5521181A (en) * | 1995-01-27 | 1996-05-28 | Abbott Laboratories | Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists |
| IT1274481B (it) * | 1995-05-12 | 1997-07-17 | Indena Spa | Composizioni farmaceutiche per il trattamento della alcol-dipendenza |
| AU751496B2 (en) * | 1997-08-28 | 2002-08-15 | Vela Pharmaceuticals Inc. | Androgen activity antagonists as therapies for anorexia, anorexia nervosa, and disorders characterized by a pathologically underweight condition |
| US6632447B1 (en) * | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| AU4100699A (en) | 1998-05-28 | 1999-12-13 | Sepracor, Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
| CA2381895A1 (en) * | 1999-08-27 | 2001-03-08 | Merck & Co., Inc. | Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome |
| US20020173495A1 (en) * | 2000-08-24 | 2002-11-21 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
| EP1374952B1 (en) * | 2001-01-17 | 2006-09-06 | Hythiam, Inc. | Use of flumazenil in developing a drug for the treatment of alcohol dependence |
| RU2322985C2 (ru) * | 2001-02-15 | 2008-04-27 | Хитиям, Инк. | Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости |
| GB0311859D0 (en) * | 2003-05-22 | 2003-06-25 | Merck Sharp & Dohme | Therapeutic agents |
| EP2343073A3 (en) * | 2003-12-11 | 2011-10-12 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| AU2006235318A1 (en) * | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
-
2006
- 2006-04-06 AU AU2006235318A patent/AU2006235318A1/en not_active Abandoned
- 2006-04-06 WO PCT/US2006/013296 patent/WO2006110642A2/en not_active Ceased
- 2006-04-06 EP EP06749649A patent/EP1868593A2/en not_active Withdrawn
- 2006-04-06 US US11/910,988 patent/US20080207601A1/en not_active Abandoned
- 2006-04-06 JP JP2008505625A patent/JP2008538748A/ja not_active Withdrawn
- 2006-04-06 CA CA002604887A patent/CA2604887A1/en not_active Abandoned
- 2006-04-07 MX MX2007012355A patent/MX2007012355A/es not_active Application Discontinuation
- 2006-04-07 WO PCT/US2006/013152 patent/WO2006110580A2/en not_active Ceased
- 2006-04-07 BR BRPI0609744-8A patent/BRPI0609744A2/pt not_active Application Discontinuation
- 2006-04-07 CA CA002603533A patent/CA2603533A1/en not_active Abandoned
- 2006-04-07 AU AU2006235257A patent/AU2006235257B2/en not_active Ceased
- 2006-04-07 KR KR1020077025774A patent/KR20080004581A/ko not_active Ceased
- 2006-04-07 KR KR1020077025773A patent/KR20080004580A/ko not_active Ceased
- 2006-04-07 EP EP06749539A patent/EP1901727A4/en not_active Withdrawn
- 2006-04-07 JP JP2008505599A patent/JP2008535852A/ja active Pending
- 2006-04-07 BR BRPI0610693A patent/BRPI0610693A2/pt not_active IP Right Cessation
- 2006-04-07 MX MX2007012353A patent/MX2007012353A/es not_active Application Discontinuation
- 2006-04-07 US US11/910,966 patent/US20080255097A1/en not_active Abandoned
- 2006-04-07 JP JP2008505580A patent/JP2008535850A/ja active Pending
- 2006-04-07 CA CA002603519A patent/CA2603519A1/en not_active Abandoned
- 2006-04-07 AU AU2006235234A patent/AU2006235234A1/en not_active Abandoned
- 2006-04-07 WO PCT/US2006/013099 patent/WO2006110557A2/en not_active Ceased
- 2006-04-07 EP EP06740761A patent/EP1868432A4/en not_active Ceased
- 2006-04-07 US US11/910,967 patent/US8012958B2/en not_active Expired - Fee Related
-
2007
- 2007-10-02 CR CR9410A patent/CR9410A/es unknown
- 2007-10-03 CR CR9413A patent/CR9413A/es not_active Application Discontinuation
- 2007-10-07 IL IL186450A patent/IL186450A0/en unknown
- 2007-10-07 IL IL186447A patent/IL186447A0/en unknown
- 2007-10-10 NO NO20075155A patent/NO20075155L/no not_active Application Discontinuation
- 2007-10-10 NO NO20075161A patent/NO20075161L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535850A5 (enExample) | ||
| Kask et al. | Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: antagonism with diazepam | |
| JP2007512371A5 (enExample) | ||
| AU4818000A (en) | Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands | |
| JP2010513569A5 (enExample) | ||
| TW200840573A (en) | Heterocyclic compounds and their methods of use | |
| WO2007092416A3 (en) | Melanin concentrating hormone receptor-1 antagonists | |
| JP6753860B2 (ja) | リルゾールの舌下製剤 | |
| MX356965B (es) | Composiciones y metodos para profilaxis y tratamiento de adicciones. | |
| JP2010537990A5 (enExample) | ||
| WO2008039431A3 (en) | Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid | |
| MXPA06002929A (es) | Metodos y reactivos para el tratamiento de desordenes inmuno-inflamatorios. | |
| Pujol et al. | Cognitive effects of labeled addictolytic medications | |
| WO2008000469A3 (en) | Nicotinic agonists selective for the alpha7 receptor subtype, the process for the preparation thereof and pharmaceutical compositions therefrom | |
| MA26964A1 (fr) | Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase. | |
| WO2008087491A3 (en) | Method for treating or preventing symptoms of hormonal variations | |
| EP3766497A1 (en) | Drug for treating cough | |
| JP2007510736A5 (enExample) | ||
| JP2002516282A5 (enExample) | ||
| NZ595545A (en) | Compositions and methods for prophylaxis and treatment of addictions | |
| EP0892641A1 (fr) | Utilisations des composes antiglucocorticoides pour le traitement des psychoses et des comportements addictifs | |
| HRP20130892T1 (hr) | Farmaceutske formulacije i njihove upotrebe u lijeäśenju ženske seksualne disfunkcije | |
| JP2008540528A5 (enExample) | ||
| WO2007114902A3 (en) | Alkylthiobenzylpiperidine compounds | |
| WO2006050002A3 (en) | Compositions for controlled delivery of pharmaceutically active compounds |